Explore the evolving landscape of Hepatitis C treatment and management in this informative lecture by Dr. Sammy Saab from UCLA's Digestive Diseases Division. Delve into topics such as decreasing prevalence, increasing hospitalizations, extrahepatic manifestations, and the evolution of therapy for Genotype 1. Discover the properties of direct-acting agents, combination therapies, and the concept of achieving a cure. Examine special populations, resistance-associated variants, and treatment regimens for various genotypes. Learn about monitoring protocols post-treatment and the challenges in improving the HCV test and cure continuum. Gain insights into model-based predictions for the changing burden of Hepatitis C virus infection and its impact on patient health metrics.
Hepatitis C – Vanishing Disease? - Sammy Saab, MD, MPH | UCLA Digestive Diseases
University of California, Los Angeles via YouTube
Overview
Syllabus
Intro
Decreasing Prevalence of Chronic Hepatitis C Infection, NHANES 2003 to 2010
Increasing Number of Hospitalizations related to HCV in Los Angeles County, 2007-2009
Extrahepatic Manifestations of Chronic Hepatitis C
Evolution of Hepatitis C Therapy Genotype 1
Hepatitis C: Achieving a Cure
Properties of Direct Acting Agents
Combination of Direct Acting Agents
Disappearing Special Populations
Cure vs Relapse Great Balance Act
Special Considerations
Resistance Associated Variants (RAV) General Principles
Resistance Testing
Treatment Regiments for Genotype 1 Patients
Treatment of non-Genotype 1 Patients
Grazoprevir and Elbasvir in Patients with Stage 4 or 5 Chronic Kidney Disease
Recommended Monitoring for patients after Antiviral Treatment
Improving the HCV Test and Cure Continuum: High Drug Costs are Not the Only Barrier
Model-Based Predictions The Changing Burden of Hepatitis C Virus Infection
Changes in CPT and MELD Scores from Baseline.
Taught by
UCLA Health
